by Muhammad Hassan Rasheed Diagnosis I’ve had an eye problem since birth. When I was around four months old, my family noticed something wasn’t right. When I used to crawl, I would bump into things, which made them think I might have a vision issue. They took me to the doctor, and that’s when we [Read More]
Author: Dan Roberts
New Drug Approved for Treatment of Macular Telangiectasia Type 2 (MacTel)
Neurotech Pharmaceuticals, Inc. has announced FDA approval of ENCELTO (revakinagene taroretcel-lwey) for the treatment of Macular Telangiectasia type 2 (MacTel). ENCELTO is the First and Only FDA-approved first and only treatment for MacTel. MacTel is a neurodegenerative disease of the retina in adults that causes progressive and irreversible vision loss, significantly impacting patients’ quality of [Read More]
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) With as few as two treatments per year, Susvimo may help people with DME maintain their vision Approval marks the second indication for Susvimo in addition to wet, or neovascular age-related macular [Read More]
Current Technology for the Blind and Visually Impaired
Assistive technology for the visually impaired is available from low-tech optical and non-optical aids to electronics and digital technology. Visually impaired and blind individuals have a tremendous number of options to eyesight, depending upon their needs, goals, and financial situations. “Ethyl”, for example, likes to talk on her landline phone. When walking, she uses a [Read More]
Genentech to Reintroduce Susvimo for People With Wet AMD
The FDA has approved updates to Susvimo, which will be available to U.S. retina specialists and patients with wet AMD in the coming weeks. Genentech announced today the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people in the United States with wet, or neovascular, age-related [Read More]